First pancreatic cancer patient in global Ph 3 registrational trial, MAPKeeper 301, to be dosed in mid-2026 December 30, 2025
Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic CRC Announced December 22, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch Ph 2a dose-expansion trial with TTX-MC138 December 15, 2025
FAILED TRIAL: Ph 3 STAR-221 study of domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility December 15, 2025
Cadonilimab Receives FDA Clearance for Global Ph 3 1L Gastric Cancer Trial vs. Nivolumab December 15, 2025
Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
Updated Efficacy Data from Ph 1/2 Transtar102 Trial of Osemitamab + Nivolumab and CAPOX in 1L G/GEJ Cancer Presented December 9, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with early gastric/GEJ cancers December 2, 2025
Positive HERIZON-GEA-01 Ph 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted New SOC in 1L HER2+ve LA/M Gastroesophageal Adenocarcinoma November 24, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
FDA aligned on the design of pivotal study of pelareorep + SOC for 1L treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) November 24, 2025
NDA accepted; PDUFA Date announced for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs November 18, 2025
